In conclusion, the comprehensive cancer immunotherapy using Zol-DCs may be beneficial for patients with locally advanced pancreatic carcinoma when used on the basis of appropriate biomarkers, such as NLR and CD8+/Treg ratio. The gene discussed is CD8A; the disease is exocrine pancreatic carcinoma.